GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Dividend Yield %

Lexeo Therapeutics (Lexeo Therapeutics) Dividend Yield % : 0.00% (As of Jun. 01, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lexeo Therapeutics Dividend Yield %?

As of today (2024-06-01), the Trailing Annual Dividend Yield of Lexeo Therapeutics is 0.00%.

The historical rank and industry rank for Lexeo Therapeutics's Dividend Yield % or its related term are showing as below:

LXEO's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.55
* Ranked among companies with meaningful Dividend Yield % only.

Lexeo Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.

As of today (2024-06-01), the Forward Dividend Yield % of Lexeo Therapeutics is 0.00%.

Lexeo Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Lexeo Therapeutics Dividend Yield % Historical Data

The historical data trend for Lexeo Therapeutics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexeo Therapeutics Dividend Yield % Chart

Lexeo Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Dividend Yield %
- - - -

Lexeo Therapeutics Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexeo Therapeutics's Dividend Yield %

For the Biotechnology subindustry, Lexeo Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexeo Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's Dividend Yield % falls into.



Lexeo Therapeutics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Lexeo Therapeutics  (NAS:LXEO) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Lexeo Therapeutics Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Lexeo Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexeo Therapeutics (Lexeo Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
345 Park Avenue South, Floor 6, New York, NY, USA, 10010
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Executives
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp, L.p. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Richard Nolan Townsend director, officer: Chief Executive Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Jenny Robertson officer: Chief Legal and Admin. Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Paul Mccormac officer: Chief Technical Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Bernard Davitian director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Eric Adler officer: Chief Scientific Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Brenda Cooperstone director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Longitude Venture Partners Iv, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Paula H Cholmondeley director 221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991
Reinaldo M Diaz director C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022
Mette Kirstine Agger director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830

Lexeo Therapeutics (Lexeo Therapeutics) Headlines